These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32201463)

  • 21. The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.
    El-Battrawy I; Demmer J; Abumayyaleh M; Crack C; Pilsinger C; Zhou X; Mügge A; Akin I; Aweimer A
    ESC Heart Fail; 2023 Apr; 10(2):943-954. PubMed ID: 36479630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.
    Docherty KF; Campbell RT; Brooksbank KJM; Dreisbach JG; Forsyth P; Godeseth RL; Hopkins T; Jackson AM; Lee MMY; McConnachie A; Roditi G; Squire IB; Stanley B; Welsh P; Jhund PS; Petrie MC; McMurray JJV
    Circulation; 2021 Jul; 144(3):199-209. PubMed ID: 33983794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
    Raphael DM; Liu Z; Jin Z; Cui X; Han D; He W; Shangguan J; Shen D
    Curr Med Res Opin; 2021 Jul; 37(7):1071-1078. PubMed ID: 33764230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study.
    Wang C; Lin Z; Miao D; Zhang H; Fu K; Zhang X; Xiao J; Hu Y; Sun Y; Wang F; Lu H; Ji X
    ESC Heart Fail; 2023 Jun; 10(3):1961-1971. PubMed ID: 36991256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients.
    Almufleh A; Marbach J; Chih S; Stadnick E; Davies R; Liu P; Mielniczuk L
    Am J Cardiovasc Dis; 2017; 7(6):108-113. PubMed ID: 29348971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status.
    Murphy SP; Ward JH; Piña IL; Felker GM; Butler J; Maisel AS; Meng X; Prescott MF; Solomon SD; Januzzi JL
    JACC Heart Fail; 2022 Dec; 10(12):976-988. PubMed ID: 36456072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of SAcubitril/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study.
    Guerra F; Ammendola E; Ziacchi M; Aspromonte V; Pellegrino PL; Del Giorno G; Dell'Era G; Pimpini L; Santoro F; Floris R; Stronati G; Nigro G; Paolisso P; Guido A; Maglia G; Brunetti ND; Carbone A; Gravellone M; Antonicelli R; Cannone M; Accogli M; Dello Russo A; Palmisano P
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1835-1842. PubMed ID: 34279677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Desai AS; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; McCague K; Abbas CA; Rocha R; Mitchell GF;
    JAMA; 2019 Sep; 322(11):1077-1084. PubMed ID: 31475296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
    Lee YH; Lin PL; Chiou WR; Huang JL; Lin WY; Liao CT; Chung FP; Liang HW; Hsu CY; Chang HY
    ESC Heart Fail; 2021 Apr; 8(2):1204-1215. PubMed ID: 33410280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy.
    Gregorietti V; Fernandez TL; Costa D; Chahla EO; Daniele AJ
    Cardiooncology; 2020 Nov; 6(1):24. PubMed ID: 33292750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application and evaluation of sacubitril/valsartan in patients with cardiac insufficiency during perioperative period of cardiac surgery.
    Peng W; Li X; Lin Y
    Exp Ther Med; 2022 Aug; 24(2):504. PubMed ID: 35837036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Echocardiographic changes in elderly patients with heart failure with reduced ejection fraction after sacubitril-valsartan treatment.
    Gu W; Xu C; Li Z; Li ZZ
    Cardiovasc Diagn Ther; 2021 Oct; 11(5):1093-1100. PubMed ID: 34815959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sacubitril/Valsartan Therapy for 14 Months Induces a Marked Improvement of Global Longitudinal Strain in Patients With Chronic Heart Failure: A Retrospective Cohort Study.
    De Vecchis R; Paccone A; Di Maio M
    Cardiol Res; 2019 Oct; 10(5):293-302. PubMed ID: 31636797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits of sacubitril/valsartan use in patients with chronic heart failure after cardiac valve surgery: a single-center retrospective study.
    Zheng J; Wu Q; Li Q; Tang M; He J; Qiu Z; Xie L; Chen L
    J Cardiothorac Surg; 2023 Apr; 18(1):138. PubMed ID: 37041595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin receptor-neprilysin inhibitors and cardiac remodeling.
    Ryazanov AS; Shikh EV; Makarovskaya MV; Kudryavtsev AA
    Braz J Med Biol Res; 2023; 56():e12616. PubMed ID: 37042870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
    Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
    Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of sacubitril/valsartan on systolic heart failure: Right heart location and clustering analysis.
    Bouali Y; Galli E; Paven E; Laurin C; Arnaud H; Oger E; Donal E
    Adv Clin Exp Med; 2022 Feb; 31(2):109-119. PubMed ID: 34918885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
    Selvaraj S; Claggett BL; Böhm M; Anker SD; Vaduganathan M; Zannad F; Pieske B; Lam CSP; Anand IS; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2020 Apr; 75(14):1644-1656. PubMed ID: 32192799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction.
    Yang P; Li X; Wang L; Wu X; Wang C; Li T; Wang H
    Front Cardiovasc Med; 2022; 9():1059420. PubMed ID: 36712243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.